Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211

Watchlist Manager
Tibet Rhodiola Pharmaceutical Holding Co Logo
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Watchlist
Price: 40.82 CNY 2.87%
Market Cap: ¥13.2B

Balance Sheet

Balance Sheet Decomposition
Tibet Rhodiola Pharmaceutical Holding Co

Balance Sheet
Tibet Rhodiola Pharmaceutical Holding Co

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2002 Dec-2003 Dec-2004 Dec-2005 Dec-2006 Dec-2007 Dec-2008 Dec-2009 Dec-2010 Dec-2011 Dec-2012 Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023 Dec-2024 Dec-2025
Assets
Cash & Cash Equivalents
79
97
87
130
93
126
105
160
132
176
218
458
300
319
373
315
529
737
768
756
929
686
1 310
1 577
Cash
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
756
927
666
1 302
1 577
Cash Equivalents
79
97
87
130
93
126
105
160
132
176
218
458
298
319
373
315
529
737
768
0
2
21
8
0
Short-Term Investments
3
4
4
0
0
0
0
1
0
0
0
0
0
0
0
0
0
90
15
538
792
515
977
1 123
Total Receivables
181
195
180
233
312
180
189
154
134
133
149
153
171
37
105
405
494
424
493
727
669
903
799
990
Accounts Receivables
55
31
53
53
79
72
58
90
56
94
109
108
125
19
61
335
379
307
333
471
447
651
527
694
Other Receivables
126
164
127
180
233
108
131
64
78
39
39
45
46
18
44
70
115
117
160
256
222
252
272
295
Inventory
16
18
47
53
72
93
206
207
235
220
219
267
306
126
94
87
62
75
71
137
100
111
134
181
Other Current Assets
18
0
4
6
17
6
14
11
15
16
33
37
34
2
68
5
2
15
4
23
222
1 187
350
767
Total Current Assets
297
314
321
422
495
405
513
532
516
545
618
914
811
484
642
812
1 088
1 341
1 351
2 182
2 712
3 403
3 570
4 637
PP&E Net
268
281
294
221
168
159
88
94
90
85
95
88
109
107
149
150
160
192
221
793
610
602
671
657
PP&E Gross
268
281
294
221
168
159
88
94
90
85
95
88
109
107
149
150
160
192
221
793
610
602
671
657
Accumulated Depreciation
11
15
20
29
27
35
35
39
46
54
74
80
78
83
95
104
109
120
132
138
245
409
467
529
Intangible Assets
81
74
68
95
92
100
68
64
57
50
39
45
34
33
1 333
1 198
1 131
1 089
965
456
418
204
185
302
Goodwill
0
0
0
0
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
84
Long-Term Investments
87
85
94
83
107
157
149
44
62
95
78
77
76
67
154
148
119
115
172
278
271
251
160
450
Other Long-Term Assets
0
0
0
0
1
2
2
1
1
3
6
7
8
6
6
14
25
22
227
84
81
119
152
137
Other Assets
0
0
0
0
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
84
Total Assets
733
N/A
754
+3%
777
+3%
821
+6%
872
+6%
832
-5%
830
0%
744
-10%
736
-1%
788
+7%
845
+7%
1 141
+35%
1 046
-8%
706
-33%
2 291
+224%
2 330
+2%
2 532
+9%
2 767
+9%
2 944
+6%
3 803
+29%
4 100
+8%
4 587
+12%
4 747
+3%
6 267
+32%
Liabilities
Accounts Payable
5
11
31
47
68
82
100
81
82
87
99
115
97
6
580
11
9
12
8
101
42
39
25
39
Accrued Liabilities
17
22
23
45
40
198
168
102
73
85
41
48
54
71
78
28
32
41
32
60
71
93
60
98
Short-Term Debt
0
0
10
60
77
88
102
130
110
90
225
104
130
0
0
0
0
0
0
534
486
500
272
800
Current Portion of Long-Term Debt
274
282
262
257
205
130
140
95
103
130
0
115
135
45
45
0
0
0
0
2
1
1
1
41
Other Current Liabilities
13
9
10
11
71
53
28
22
29
25
76
332
190
71
902
225
220
257
293
412
426
552
409
662
Total Current Liabilities
308
323
335
420
460
550
538
430
396
417
442
714
605
192
1 605
264
261
310
333
1 110
1 026
1 184
767
1 640
Long-Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
2
1
1
0
436
Deferred Income Tax
0
0
0
0
0
0
0
0
0
0
0
1
1
0
1
1
0
0
2
16
14
2
1
25
Minority Interest
5
4
9
8
10
5
4
4
5
15
14
11
10
4
2
2
5
10
12
15
19
29
34
339
Other Liabilities
6
7
7
7
7
7
13
14
16
16
18
25
26
28
27
20
14
10
11
31
28
26
27
28
Total Liabilities
319
N/A
334
+5%
351
+5%
436
+24%
478
+10%
563
+18%
554
-2%
448
-19%
416
-7%
448
+8%
474
+6%
749
+58%
642
-14%
217
-66%
1 630
+651%
287
-82%
280
-3%
330
+18%
368
+12%
1 172
+218%
1 088
-7%
1 243
+14%
830
-33%
2 469
+198%
Equity
Common Stock
123
123
123
123
123
139
139
139
146
146
146
146
146
146
146
180
180
177
248
248
248
248
322
322
Retained Earnings
53
59
65
24
33
92
85
65
42
21
9
26
39
123
294
464
610
856
1 086
1 169
1 455
1 773
2 330
2 664
Additional Paid In Capital
239
239
239
239
239
222
222
222
216
216
217
217
217
217
217
1 409
1 409
1 327
1 264
1 265
1 266
1 263
1 188
752
Unrealized Security Profit/Loss
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
Other Equity
0
0
0
0
0
0
0
0
0
0
0
3
4
4
5
9
54
78
22
51
43
61
78
56
Total Equity
414
N/A
420
+1%
426
+1%
385
-10%
395
+2%
269
-32%
276
+2%
296
+7%
320
+8%
340
+6%
372
+9%
391
+5%
404
+3%
490
+21%
661
+35%
2 043
+209%
2 253
+10%
2 437
+8%
2 576
+6%
2 630
+2%
3 012
+15%
3 345
+11%
3 918
+17%
3 798
-3%
Total Liabilities & Equity
733
N/A
754
+3%
777
+3%
821
+6%
872
+6%
832
-5%
830
0%
744
-10%
736
-1%
788
+7%
845
+7%
1 141
+35%
1 046
-8%
706
-33%
2 291
+224%
2 330
+2%
2 532
+9%
2 767
+9%
2 944
+6%
3 803
+29%
4 100
+8%
4 587
+12%
4 747
+3%
6 267
+32%
Shares Outstanding
Common Shares Outstanding
194
194
194
194
194
194
194
194
204
204
204
204
204
204
204
252
252
248
248
322
322
248
322
322
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett